L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
Development and sales of solutions for preventing the worsening of diabetes complications.
Development of technology for assessing micronutrient intake using hair and provision of analysis services.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
NUProtein develops next-generation protein and bioactive compound production technologies using genetically engineered rice. By cultivating high-expression rice and extracting target components directly from the grain, the company achieves exceptionally low-cost and stable production compared with conventional methods. NUProtein is also recognized as one of the world’s five industrial players in cell-free protein synthesis and gene-related patents. Through low-cost growth factors and other functional proteins, the company is building a new supply chain for the cultivated meat and broader food-tech sectors.
